CLLS

Healthcare Biotechnology

Cellectis S.A.

$1.43

-0.00 -0.00% today

Price History

Not enough data

Key Stats

Market Cap

144.03M

Avg Volume

76,653

EPS

-$0.61

52W High

$5.48

52W Low

$1.25

Div. Yield

0.0%

Analyst Ratings

Hold

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-2.31

P/B Ratio

2.53

P/S Ratio

2.26

EV/EBITDA

-0.38

EV/Revenue

0.28

Margins

Gross Margin 100.0%

Operating Margin (340.7%)

Net Margin (102.3%)

EBITDA Margin (73.1%)

Growth & Returns

Revenue Growth (YoY)

(62.1%)

Return on Equity

(94.5%)

Return on Assets

(11.7%)

Liquidity & Leverage

Current Ratio

1.37

Quick Ratio

1.34

Debt / Equity

1.96

Total Cash

166.69M

Total Debt

80.35M

About

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.